GSK shareholders to vote on Novartis megadeal in December

Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline ($GSK) and Novartis ($NVS) worth more than $20 billion. The British pharma giant has asked its investors to vote at a Dec. 18 meeting on the proposed deal, which will send GSK's oncology drugs to Switzerland and most of Novartis' flu business to Glaxo, as well as establish a consumer healthcare JV. "This is the most significant transaction for the company since the creation of GlaxoSmithKline in 2000," GSK chairman Christopher Gent wrote in a shareholder letter seen by ReutersNews | More